{"created":"2021-03-01T06:11:02.217925+00:00","id":7188,"links":{},"metadata":{"_buckets":{"deposit":"18c8c0d2-f15e-4448-b653-26765de2b0c9"},"_deposit":{"id":"7188","owners":[],"pid":{"revision_id":0,"type":"depid","value":"7188"},"status":"published"},"_oai":{"id":"oai:soar-ir.repo.nii.ac.jp:00007188","sets":["461:848:849"]},"author_link":["17400","17401","17402","17403","17404","17405","17406","17407","17408"],"item_1628147817048":{"attribute_name":"出版タイプ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_6_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2013-03","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageStart":"450","bibliographicVolumeNumber":"30","bibliographic_titles":[{"bibliographic_title":"MEDICAL ONCOLOGY"}]}]},"item_6_description_19":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"信州大学博士（医学）・学位論文・平成24年3月31日授与（甲第939号）・立石 一成","subitem_description_type":"Other"},{"subitem_description":"The final publication is available at www.springerlink.com.","subitem_description_type":"Other"}]},"item_6_description_20":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"The clinical efficacy and outcomes of gefitinib therapy as a first-line treatment for elderly patients with non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations were analyzed retrospectively. We analyzed chemotherapy-naive NSCLC patients aged 75 years or older who had EGFR mutations (exon 19 deletion mutation or L858R), who were initially treated with gefitinib (250 mg) once daily in Nagano Prefecture. A total of 55 patients (16 men, 39 women) with a median age of 81.1 years (range; 75-94 years) treated between April 2007 and July 2012 were analyzed. The overall response rate and disease control rate were 72.7 % (95 % confidence interval (CI); 59.5-82.9 %) and 92.7 % (95 % CI; 82.0-97.6 %), respectively. Median progression-free survival and overall survival from the start of gefitinib treatment were 13.8 months (95 % CI; 9.9-18.8 months) and 29.1 months (95 % CI; 22.4 months-not reached), respectively. Two-year survival rate was 59.5 % (95 % CI; 41.0-78.0 %). Major grade 3 toxicities were skin rash (1.8 %) and increased levels of aspartate aminotransferase or alanine aminotransferase (7.3 %). First-line treatment with gefitinib for elderly EGFR-mutated NSCLC patients was effective and well tolerated. The results suggest that first-line gefitinib should be considered as a preferable standard treatment in elderly patients with advanced NSCLC harboring EGFR mutations.","subitem_description_type":"Abstract"}]},"item_6_description_30":{"attribute_name":"資源タイプ（コンテンツの種類）","attribute_value_mlt":[{"subitem_description":"Article","subitem_description_type":"Other"}]},"item_6_description_5":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"MEDICAL ONCOLOGY. 30(1):45 (2013)","subitem_description_type":"Other"}]},"item_6_publisher_4":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"HUMANA PRESS INC"}]},"item_6_relation_48":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"10.1007/s12032-012-0450-2"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1007/s12032-012-0450-2","subitem_relation_type_select":"DOI"}}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Tateishi,  Kazunari"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ichiyama,  Takashi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Hirai,  Kazuya"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Agatsuma,  Toshihiko"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Koyama,  Shigeru"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Hachiya,  Tsutomu"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Morozumi,  Nobutoshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Shiina,  Takayuki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Koizumi,  Tomonobu"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2015-09-25"}],"displaytype":"detail","filename":"H24Kou939_Tateishi.pdf","filesize":[{"value":"612.7 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"H24Kou939_Tateishi.pdf","url":"https://soar-ir.repo.nii.ac.jp/record/7188/files/H24Kou939_Tateishi.pdf"},"version_id":"5a493309-919c-43b2-b604-5ffc1522aa04"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Clinical outcomes in elderly patients administered gefitinib as first-line treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer: retrospective analysis in a Nagano Lung Cancer Research Group Study","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Clinical outcomes in elderly patients administered gefitinib as first-line treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer: retrospective analysis in a Nagano Lung Cancer Research Group Study","subitem_title_language":"en"}]},"item_type_id":"6","owner":"1","path":["849"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2014-06-27"},"publish_date":"2014-06-27","publish_status":"0","recid":"7188","relation_version_is_last":true,"title":["Clinical outcomes in elderly patients administered gefitinib as first-line treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer: retrospective analysis in a Nagano Lung Cancer Research Group Study"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2022-12-14T03:54:12.104754+00:00"}